Mannkind Denied Again by FDA

Back in January, Mannkind Corporation (MNKD) was denied yet again by the US FDA for its approval of the inhaled insulin spray Afrezza. The company subsequently laid off about 40% of its work force and shares were hammered after a conference call held by founder and CEO Alfred Mann - who has roughly a billion dollars of his own money invested in Mannkind and its flagship product Afrezza - failed to convince investors that he would front additional cash of his own to conduct the additional trial requested by the FDA as a prerequisite for approval.

Mr. Mann later clarified his statements and stressed that he - and the rest of the Mannkind staff - were 100% behind the continued development of Afrezza.

It has since been speculated that Mannkind will look to....
CLICK HERE FOR FULL ARTICLE